What is Colossal Biosciences?
Biotechnology company using genomics and synthetic biology for de-extinction and conservation.
- Category
- De-extinction biotechnology
- Headquarters
- Dallas, Texas
- Founded
- 2021
- Employees
- Private; reported 170+ employees in 2025 coverage
- Total funding
- $435 million reported as of January 2025
- Valuation
- $10.2 billion reported after Series C
What is Colossal Biosciences?
Colossal Biosciences is a de-extinction biotechnology company headquartered in Dallas, Texas.
Colossal uses genomics, gene editing, reproductive technologies, and computational biology to pursue de-extinction and conservation programs for species such as the woolly mammoth, thylacine, and dodo. The company operates a research platform and conservation foundation rather than a conventional SaaS product; customer revenue is not public.
The company was founded in 2021 and remains private. Its public profile is strongest around Mammoth program and Thylacine program, while detailed revenue figures are not publicly disclosed.
As of June 2026, the safest public read is that Colossal Biosciences is scaling through enterprise partnerships and capital-intensive product development rather than a self-serve consumer motion.
Sources:Colossal websiteColossal news
What does Colossal Biosciences offer?
Colossal Biosciences's public product set centers on Mammoth program, Thylacine program, Dodo program.
- Mammoth program· De-extinction
- Thylacine program· De-extinction
- Dodo program· De-extinction
- Colossal Foundation· Conservation
Sources:Colossal website
How does Colossal Biosciences make money?
Platform biotech model funded by venture capital, partnerships, IP, and conservation programs; no software pricing is public.
Platform biotech model funded by venture capital, partnerships, IP, and conservation programs; no software pricing is public. No public product pricing; biotechnology R&D company.
Growth is driven by enterprise adoption, strategic partnerships, and proof that the platform can deliver measurable operational, clinical, scientific, or mission outcomes. Because Colossal Biosciences does not publish standard list prices, buyers should treat budget sizing as a custom-contract exercise.
The commercial motion therefore depends on executive sponsorship, security and compliance review, and evidence that the product can integrate into existing workflows rather than replace them all at once.
Who leads Colossal Biosciences?
Colossal Biosciences is led by Ben Lamm, Co-founder and CEO.
- Ben LammCo-founder and CEOCo-founder · since 2021Serial entrepreneur leading commercialization and partnerships.
- George ChurchCo-founderCo-founderHarvard geneticist and synthetic-biology pioneer.
- Andrew PaskChief Biology Officer / Thylacine leadExecutiveLeads thylacine restoration work and Australian expansion.
How do you contact Colossal Biosciences's leadership?
Public contact form; no verified personal email pattern found. Use the listed public company route rather than guessed personal inboxes.
Public contact form; no verified personal email pattern foundSources:Colossal website
How much funding has Colossal Biosciences raised?
Colossal Biosciences has $435 million reported as of january 2025 and is private.
2021: Seed/Series A — $15 million, led/backed by Breyer Capital and others. 2022: Series A/B — $60 million, led/backed by Thomas Tull and investors. 2023: Series B — $150 million, led/backed by United States Innovative Technology Fund. 2025: Series C — $200 million, led/backed by TWG Global and investors ($10.2 billion valuation).
The latest public valuation/status marker is $10.2 billion reported after Series C. Where a valuation is undisclosed, public reporting only supports the financing amount and participating investors.
Funding is best interpreted as capacity for product build-out, hiring, regulatory or deployment work, and longer sales cycles; it should not be read as proof of profitability unless the company has separately disclosed profitability.
How did Colossal Biosciences get here?
Colossal Biosciences's timeline runs from its 2021 founding through major financing and product milestones.
- 2021FoundedColossal launched with woolly mammoth de-extinction as its first program.
- 2022Thylacine programThe company announced work to restore the Tasmanian tiger.
- 2023Dodo programColossal added dodo restoration work.
- 2025Series C decacorn roundColossal raised $200 million at a reported $10.2 billion valuation.
- 2025Australia expansionColossal expanded through thylacine research operations in Australia.
Sources:Colossal websiteColossal news
Who are Colossal Biosciences's competitors?
Colossal Biosciences competes with specialized startups and larger platform companies in de-extinction biotechnology.
Colossal Biosciences — frequently asked questions
